Endo Announces Five Presentations at the Sexual Medicine Society of North America (SMSNA) Annual Meeting
DUBLIN, Nov. 16, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that five new presentations related to Peyronie's disease, or PD, and XIAFLEX® (collagenase clostridium histolyticum, or CCH, injection 0.9 mg) will be shared during the Sexual Medicine Society of North America (SMSNA) annual meeting, taking place November 16-19 in San Diego.
- DUBLIN, Nov. 16, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that five new presentations related to Peyronie's disease, or PD, and XIAFLEX® (collagenase clostridium histolyticum, or CCH, injection 0.9 mg) will be shared during the Sexual Medicine Society of North America (SMSNA) annual meeting, taking place November 16-19 in San Diego.
- "The relatively common condition of Peyronie's disease—estimated to affect 1 in 10 men in the U.S.—remains under-studied and is often misunderstood," said Dr. Jesse Mills, urologist and presenter of the data analysis poster.
- "Efforts like the post hoc analysis of XIAFLEX® Phase 3 data and the new landmark registry aim to advance medical knowledge of PD and support patient outcomes."
- The five new Endo-sponsored and Endo-supported presentations are below:
Peyronie's Disease Patients with Penile Pain at Baseline Treated with Collagenase Clostridium Histolyticum: A Post Hoc Analysis
Outcomes of Collagenase Clostridium Histolyticum in Men with Ventral Curvatures: An Updated Series
Efficacy of a Novel Collagenase Clostridium Histolyticum Protocol for Peyronie's Disease Among Prior Non-responders: A Randomized, Controlled, Single-Blinded Study
Comparison of Collagenase Clostridium Histolyticum to Surgery for the Management of Peyronie's Disease: A Randomized Trial – 1 Year Outcomes